A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Clinical Trial Grant
Awarded By
Calithera Biosciences, Inc.
Start Date
April 2, 2019
End Date
February 8, 2024
Awarded By
Calithera Biosciences, Inc.
Start Date
April 2, 2019
End Date
February 8, 2024